Cancer epigenetics: promises and pitfalls for cancer therapy

FEBS J. 2022 Mar;289(5):1156-1159. doi: 10.1111/febs.16395.

Abstract

Over the past few decades, epigenetic regulators have emerged as major players in cellular processes that drive cancer initiation and progression, and subsequently modulate the responsiveness of cancers to therapeutic agents. This Special Issue of The FEBS Journal, Cancer Epigenetics, features an exciting collection of review articles that focus on the functions of a broad spectrum of epigenetic modulators in cancer. The diverse topics explored herein range from the roles of transposable elements and chromatin architecture in cancer and the most recent research advances on cancer-associated histone variants (oncohistones), to the effects of altered epigenetics on transcription and advanced cancer cell phenotypes. Moreover, the prospective key function of cancer metabolism in linking epigenetics and transcriptional regulation, and the potential of epigenetics for targeted cancer therapeutics is discussed. We hope that this collection of articles will give readers an enlightening overview of the most recent advances in the fast-moving field of cancer epigenetics.

Keywords: DNA methylation; cancer epigenetics; chromatin; histone modifications; transcriptional regulation.

Publication types

  • Editorial
  • Introductory Journal Article

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Chromatin / chemistry
  • Chromatin / drug effects
  • Chromatin / metabolism
  • DNA Methylation*
  • DNA Transposable Elements
  • Disease Progression
  • Epigenesis, Genetic*
  • Histones / genetics*
  • Histones / metabolism
  • Humans
  • Neoplasm Proteins / genetics*
  • Neoplasm Proteins / metabolism
  • Neoplasms / diagnosis
  • Neoplasms / drug therapy*
  • Neoplasms / genetics*
  • Neoplasms / pathology
  • Phenotype
  • Transcription, Genetic
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Chromatin
  • DNA Transposable Elements
  • Histones
  • Neoplasm Proteins